1Yeh RW,Sidney S,Chandra M. Population trends in the incidence and outcomes of acute myocardial infarction[J].New England Journal of Medicine,2010,(23):2155-2165.
2Yusuf S,Mehta SR,Chrolavicius S. Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J].New England Journal of Medicine,2006,(14):1464-1476.
3Yusuf S,Mehta SR,Chrolavicius S. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction:the OASIS-6 randomized trial[J].Journal of the American Medical Association,2006,(13):1519-1530.
4Mega JL,Braunwald E,Wiviott SD. Rivaroxaban in patients with a recent acute coronary syndrome[J].New England Journal of Medicine,2012,(01):9-19.
5Lincoff AM,Bittl JA,Harrington RA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention:REPLACE-2 randomized trial[J].Journal of the American Medical Association,2003,(07):853-863.
6Stone GW,McLaurin BT,Cox DA. Bivalirudin for patients with acute coronary syndromes[J].New England Journal of Medicine,2006,(21):2203-2216.
